REG - Solvonis Therapeutic - Raises £1.25 Million to Accelerate Programmes

Solvonis TherapeuticsAnnouncement

Yesterday 07:00

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20251016:nRSP5667Da&default-theme=true

RNS Number : 5667D  Solvonis Therapeutics PLC  16 October 2025

THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION FOR THE PURPOSES OF ARTICLE 7 OF
EU REGULATION 596/2014 AS IT FORMS PART OF DOMESTIC LAW IN THE UNITED KINGDOM
BY VIRTUE OF THE EUROPEAN UNION (WITHDRAWAL) ACT 2018. UPON THE PUBLICATION OF
THIS ANNOUNCEMENT VIA A REGULATORY INFORMATION SERVICE, THIS INSIDE
INFORMATION WILL BE CONSIDERED TO BE IN THE PUBLIC DOMAIN.

 

16 October 2025
Solvonis Therapeutics plc

("Solvonis" or the "Company")

Raises £1.25 Million to Accelerate Programmes in High-Burden CNS Disorders

Solvonis Therapeutics plc (LSE: SVNS), an emerging biopharmaceutical company
developing novel medicines for high-burden central nervous system ("CNS")
disorders, is pleased to announce that it has successfully raised £1.25
million (gross) through a direct subscription with certain institutional and
existing strategic investors (the "Subscription").

The Subscription was priced at £0.0033 per new ordinary share, representing
approximately an 13% discount to the closing mid-market price on 15 October
2025, and will result in the issue of 378,787,876 new ordinary shares of
£0.001 each ("New Ordinary Shares"). The New Ordinary Shares will rank pari
passu in all respects with the Company's existing ordinary shares. Application
will be made for the New Ordinary Shares to be admitted to trading on the Main
Market of the London Stock Exchange ("Admission"), which is expected to occur
on or around 22 October 2025.

Use of Proceeds

Together with the Company's existing resources, the proceeds will enable
Solvonis to broaden its research and development activities, deepening its
work within addiction and psychiatry while extending early discovery into
neurology, establishing a unified focus on high-burden CNS diseases across
three strategic pillars: addiction, psychiatry, and neurology.

Through this investment, Solvonis will:

·      Continue advancing its clinical and pre-clinical programmes
across these CNS pillars;

·      Expand the reach of its  CNS drug-discovery programme, which
integrates computational chemistry, predictive modelling, and laboratory
validation to identify and optimise novel small-molecule modulators relevant
across its three pillars; and

·      Strengthen internal R&D and translational capabilities to
enable deeper evaluation of new targets and mechanisms addressing the unmet
needs driving the world's most high-burden CNS disorders.

This fundraise marks the first step in implementing Solvonis' expanded
three-pillar CNS strategy and provides a foundation for continued scientific,
clinical, and partnering progress across the Company's diversified pipeline.

Anthony Tennyson, Chief Executive Officer, commented "This financing marks an
important time  for Solvonis as we evolve into a broader CNS
biopharmaceutical company. Our focus now spans addiction, psychiatry, and
neurology - three interlinked areas of enormous unmet need. The continued
support of our core investors enables us to accelerate our discovery work and
deepen our development programmes across these pillars, advancing our mission
to deliver innovative therapies for high-burden CNS disorders."

Admission and Total Voting Rights

Application will be made for the New Ordinary Shares to be admitted to trading
on the Main Market of the London Stock Exchange and to listing in the FCA's
Official List Equity Shares (transition) category ("Admission"). It is
expected that Admission will become effective at 8.00 a.m. on or around 22
October 2025.

Following Admission, the Company's issued ordinary share capital will comprise
6,782,767,131 ordinary shares of £0.001 each. This figure may be used by
shareholders in the Company as the denominator for the calculations by which
they will determine if they are required to notify their interest in, or a
change in their interest in, the share capital of the Company under the FCA's
Disclosure Guidance and Transparency Rules.

 

Enquiries:

Solvonis Therapeutics plc

Anthony Tennyson, CEO & Executive Director

anthony@solvonis.com

Singer Capital Markets (Broker)

Phil Davies

+44 (0) 20 7496 3000

About Solvonis Therapeutics plc

Solvonis Therapeutics plc (LSE: SVNS) is an emerging biopharmaceutical company
developing novel small-molecule therapeutics for high-burden central nervous
system (CNS) disorders. Headquartered in London and listed on the main market
of the London Stock Exchange, Solvonis is advancing a differentiated pipeline
of repurposed and novel compounds across addiction, psychiatry, and neurology.

The Company's lead programmes address Alcohol Use Disorder (AUD) and
Post-Traumatic Stress Disorder (PTSD), with additional discovery work
supporting expansion into broader CNS indications. Its lead asset, SVN-001, is
currently in Phase 3 for severe AUD in the UK, while SVN-002 is preparing for
a Phase 2b trial in the US targeting moderate-to-severe AUD. The preclinical
PTSD programme (SVN-SDN-14) leverages novel serotonin-dopamine modulators
designed to enhance pro-social behaviour and long-term outcomes.

In parallel, Solvonis is advancing proprietary CNS discovery programmes built
on a dedicated compound library to identify new small-molecule modulators of
key neurotransmitter systems. This platform enables efficient early-stage
innovation and supports the Company's integrated approach to developing
therapies across its three strategic pillars.

With a capital-efficient model, dual development strategy, and near-term
partnering opportunities, Solvonis is positioned to deliver sustained value
through innovation in CNS therapeutics.

solvonis.com (https://solvonis.com) | LinkedIn
(https://www.linkedin.com/company/solvonis) | X (Twitter)
(https://x.com/Solvonis)

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  ALSVELFFEBLBFBD



            Copyright 2019 Regulatory News Service, all rights reserved